Surrozen Inc (SRZN)
11.12
+0.12
(+1.14%)
USD |
NASDAQ |
May 31, 16:00
11.14
+0.02
(+0.13%)
After-Hours: 20:00
Surrozen Enterprise Value: 8.297M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 8.297M |
| May 30, 2024 | 7.897M |
| May 29, 2024 | 8.057M |
| May 28, 2024 | 6.073M |
| May 24, 2024 | 6.135M |
| May 23, 2024 | 5.625M |
| May 22, 2024 | 6.457M |
| May 21, 2024 | 3.770M |
| May 20, 2024 | 2.971M |
| May 17, 2024 | 3.258M |
| May 16, 2024 | 5.178M |
| May 15, 2024 | 5.186M |
| May 14, 2024 | 6.136M |
| May 13, 2024 | 5.625M |
| May 10, 2024 | 5.977M |
| May 09, 2024 | 5.433M |
| May 08, 2024 | 5.338M |
| May 07, 2024 | 4.57M |
| May 06, 2024 | 5.497M |
| May 03, 2024 | 4.698M |
| May 02, 2024 | 5.018M |
| May 01, 2024 | 4.346M |
| April 30, 2024 | 7.129M |
| April 29, 2024 | 2.427M |
| April 26, 2024 | 1.435M |
| Date | Value |
|---|---|
| April 25, 2024 | 0.2517M |
| April 24, 2024 | 1.403M |
| April 23, 2024 | 1.531M |
| April 22, 2024 | 2.299M |
| April 19, 2024 | 2.795M |
| April 18, 2024 | 2.555M |
| April 17, 2024 | 2.651M |
| April 16, 2024 | 2.522M |
| April 15, 2024 | 3.898M |
| April 12, 2024 | 7.033M |
| April 11, 2024 | 8.169M |
| April 10, 2024 | 7.929M |
| April 09, 2024 | 9.016M |
| April 08, 2024 | 8.632M |
| April 05, 2024 | -3.841M |
| April 04, 2024 | -3.42M |
| April 03, 2024 | -4.663M |
| April 02, 2024 | -7.339M |
| April 01, 2024 | -6.011M |
| March 28, 2024 | -3.633M |
| March 27, 2024 | -6.484M |
| March 26, 2024 | -7.883M |
| March 25, 2024 | -8.028M |
| March 22, 2024 | -7.574M |
| March 21, 2024 | -7.553M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-65.18M
Minimum
Dec 16 2022
372.20M
Maximum
Sep 16 2021
11.67M
Average
-10.14M
Median
Enterprise Value Benchmarks
| CEL-SCI Corp | 60.22M |
| AIM ImmunoTech Inc | 10.88M |
| IGC Pharma Inc | 29.80M |
| NovaBay Pharmaceuticals Inc | 4.387M |
| Protalix BioTherapeutics Inc | 54.78M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.83M |
| Total Expenses (Quarterly) | 9.13M |
| EPS Diluted (Quarterly) | -4.24 |
| Earnings Yield | -165.1% |